Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-166-8 | CAS number: 28701-67-9
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Assessment of the toxicokinetic behaviour of the substance to the extent that could be derived from the relevant available information
- Type of information:
- other: Assessment (literary search)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2020
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- no
Test material
- Reference substance name:
- 3-(isodecyloxy)propylammonium acetate
- EC Number:
- 249-166-8
- EC Name:
- 3-(isodecyloxy)propylammonium acetate
- Cas Number:
- 28701-67-9
- Molecular formula:
- C13H29NO.C2H4O2
- IUPAC Name:
- 3-[(8-methylnonyl)oxy]propan-1-aminium acetate
- Test material form:
- liquid
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 457 other: mg/kg
- Remarks:
- EPA Guideline Series 81-1
LD50 (male), 95 % confidence limits: 1271 to 1670 mg/kg)
- Dose / conc.:
- 1 033 other: mg/kg
- Remarks:
- EPA Guideline Series 81-1
LD50 (female), 95% confidence limits: 881 to 1212 mg/kg)
- Dose / conc.:
- 200 mg/kg bw/day
- Remarks:
- BIO Acute dermal
- Dose / conc.:
- 1 000 mg/kg bw/day
- Remarks:
- BIO acute dermal
- Dose / conc.:
- 2 000 mg/kg bw/day
- Remarks:
- BIO acute dermal
- Dose / conc.:
- 3.48 mg/L air
- Remarks:
- BIO acute inhalation
- Dose / conc.:
- 100 mg/kg bw/day
- Remarks:
- BIO DRFE 14 oral
- Dose / conc.:
- 300 mg/kg bw/day
- Remarks:
- BIO RDFE 14 oral
- Dose / conc.:
- 600 mg/kg bw/day
- Remarks:
- BIO RDFE 14 oral
- Dose / conc.:
- 900 mg/kg bw/day
- Remarks:
- BIO RDFE 14 oral
- Dose / conc.:
- 50 mg/kg bw/day
- Remarks:
- BIO 28 oral
- Dose / conc.:
- 150 mg/kg bw/day
- Remarks:
- BIO 28 oral
- Dose / conc.:
- 300 mg/kg bw/day
- Remarks:
- BIO 28 oral
- Dose / conc.:
- 62.5 mg/kg bw/day
- Remarks:
- BIO RPD screening
- Dose / conc.:
- 125 mg/kg bw/day
- Remarks:
- BIO RPD screening
- Dose / conc.:
- 250 mg/kg bw/day
- Remarks:
- BIO RPD screening
- Details on dosing and sampling:
- TOXICOKINETIC / PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled (delete / add / specify): urine, faeces, blood, plasma, serum or other tissues, cage washes, bile
- Time and frequency of sampling:
- Other:
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled (delete / add / specify): urine, faeces, tissues, cage washes, bile
- Time and frequency of sampling:
- From how many animals: (samples pooled or not)
- Method type(s) for identification (e.g. GC-FID, GC-MS, HPLC-DAD, HPLC-MS-MS, HPLC-UV, Liquid scintillation counting, NMR, TLC)
- Limits of detection and quantification:
- Other:
TREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable):
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- Absorption from gastrointestinal tract for 1 mg dose (%) = 100 (Lipinski's Rule-of-five score (bioavailability) = 0), EQUATION FROM LITERATURE
- Type:
- absorption
- Results:
- Absorption from gastrointestinal tract for 1000 mg dose (%) = 95 (Lipinski's Rule-of-five score (bioavailability) = 0), EQUATION FROM LITERATURE
- Type:
- absorption
- Results:
- Dermal absorption (mg/cm2/event) 0.0179 (EPI DERMWIN)
- Type:
- distribution
- Results:
- Log brain/blood partition coefficient 0.4955 (EQUATION FROM LITERATURE)
Applicant's summary and conclusion
- Executive summary:
The chemical evaluated ( 3-(isodecyloxy)propylammonium acetate )belongs to cationic surfactants. The literature sources mentioned that cationic surfactants are substances of low acute toxicity and exhibit strongly irritation effect exhibit on the mucous membrane of the gastrointestinal tract (SFT 1991,SCCSand others).
This is in agreement with findings of above mentioned studies.
Isomaa and Ekman (1975) stated thatadministrations of quaternary ammonium surfactant to pregnant mice in an ip dose corresponding to 10 or 33% of the LD50 increased the incidence of malformations, principally cleft palate and minor skeletal defects in the skull and sternum. Cationic surfactants are known to affect the permeability of cells and tissues and it is possible that the embryotoxic and teratogenic effects are due to a disturbance of the functional integrity of the placenta.
This is not the case of our chemical.
Isomaa (1975)studied the absorption, distribution and excretion of orally administered [14C]CTAB, (the same quaternary ammonium surfactant mentioned above), in female rats. About 80% of the dose of radioactivity was found in the gastro-intestinal tract 8 hr after administration, only small amounts were found in the blood plasma and about 2% of the administered radioactivity was excreted in the bile during the first 12 hr after treatment. The low levels of radioactivity in the serum and bile, together with the large amounts of radioactivity found in the gastro-intestinal tract, indicated poor intestinal absorption of CTAB. Only small amounts of radioactivity were found in the liver, kidneys, spleen, heart, lungs and skeletal muscle, and the tissue radioactivity declined rapidly. Within 3 days of ingestion, 92% of the administered radioactivity had been excreted in the faeces and 1% in the urine.
These findings are in large extent in agreement with the resulst of studies mentioned in part 2 of assessment report.
QSAR models estimated for the chemical evaluated the poor dermal absorption, very good absorption from gastrointestinal tract and for bioavailability the score 0 (Lipinskiscores of 0 or 1 means that the substance may be bioavailable).
With this last statement we could identify.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
